VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. [electronic resource]
Producer: 20120920Description: 724-33 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Base Sequence
- Bevacizumab
- Biomarkers
- Carcinoma, Renal Cell -- drug therapy
- Clinical Trials, Phase III as Topic
- Female
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Molecular Sequence Data
- Pancreatic Neoplasms -- drug therapy
- Polymorphism, Single Nucleotide
- Proportional Hazards Models
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-1 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.